Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programmes

Contributed by: GlobeNewswire

Tags

Partnership

More Like This

Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy

PR Newswire associated0

Department of Health - Abu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases

Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders

Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants

Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases

PR Newswire associated0

OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product

ALSA Ventures launches novel Gene Therapy portfolio company Axovia Therapeutics to treat Ciliopathies